type of report	Current report
number	33/2012
company	PHARMENA

## June 2012 monthly report

The Management Board of Pharmena S.A. hereby presents its monthly report for June 2012

1. Information on trends and events occurring in the Issuer's market environment

To the best knowledge of the Management Board, in June 2012 no trends or events occurred in the Issuer's market environment which could significantly influence financial results of the company.

In June 2012, Pharmena S.A. developed its network of sales and carried out marketing actions in order to increase sales profit from its marketed products.

In June 2012, the Company notified Chief Sanitary Inspectorate (Department of Functional Food) about placing of Dermena Complex dietary supplement on the market. Dermena Complex is a dietary supplement in capsules that impedes hair loss. The product's sale will enable the Company to enter a new segment of the market. The market of dietary supplements in category "Hair, skin, and nails" was estimated at 76 million PLN in 2010 (according to IMS). It is the Company's objective to reach 10% market share within 2-3 years from the introduction of the product.

Also, during the period covered by this report, the Issuer commenced cooperation with pharmaceutical wholesaler PDF Slawex Sp. z o.o., which has over 20-year experience and over 3,000 customers.

The above steps lie within the realisation the Company's updated Strategy for 2012-2015 in the scope of dermatological activities (the Issuer informed about the strategy's assumptions in current report no. 16/2012 of 13<sup>th</sup> April 2012).

In June 2012, the Company continued its research and development work on new products and searched for new applications for active substances protected by patents and patent applications owned by the Company.

2. Achievement of the goals of an issue

In June 2012, Pharmena S.A. did not make any money expenditure directly on issue-related purposes. However, a subsidiary company Cortria Corporation spent in June 2012 its funds on production of tablets for the planned clinical trials.

3. A list of all information published by the Issuer in the form of current reports in the reporting period from  $1^{st}$  June 2012 to  $30^{th}$  June 2012

During the period covered by this report, Pharmena S.A. published the following reports in EBI system:

Current report no. 27/2012 of 1<sup>st</sup> June 2012 – Notification upon placing of Dermena Complex dietary supplement on the market

Current report no. 28/2012 of 5<sup>th</sup> June 2012 – Commencing cooperation with PDF Slawex Sp. z o.o.

Current report no. 29/2012 of 13<sup>th</sup> June 2012 – May 2012 monthly report

Current report no. 30/2012 of 29<sup>th</sup> June 2012 – Court registration of the changes to Articles of Association

During the period covered by this report, Pharmena S.A. did not publish any reports in ESPI system.

4. Investor's calendar for July 2012

5<sup>th</sup> July 2012 – dividend payment

Publication of July 2012 monthly report until 14<sup>th</sup> August 2012

Legal basis: Resolution No. 795/2008 of the Warsaw Stock Exchange Management Board dated 31<sup>st</sup> November 2008 concerning the adoption of the codes of best practice applicable on the NewConnect market, Appendix 1, point 16.

Representatives of the company:

- Konrad Palka President of the Board
- Marzena Wieczorkowska Vice President of the Board